Despite Only Two Parallel Review Success Stories, CMS Touts Better Coordination

While only two devices have received approval and a national coverage determination through US FDA/CMS' parallel review program, a top CMS official says industry needs to look beyond just the numbers. Instead, she says the parallel review program is part of a sea-change that has allowed for better communication between CMS, FDA and sponsors.

FDA CMS

More from Policy & Regulation

More from Medtech Insight